Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

Read Press Release

Full-stack In vitro and Genetic Tox services

Screening to IND

Know more

Establishing the simple complex

Route to a successful large molecule bioanalytical sample analysis

Read Viewpoint

Research that changes the world for the better

We are accelerating drug innovation and development for companies globally

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

InstaVisit – Visit Syngene virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

View Now

0 +

Active Clients

Collaborations with top 20 Pharma/Biotech companies

5200 +

Scientists

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents

Latest News

View all

Indian CDMOs expand capacities with Syngene taking the lead

News

2nd Apr, 2024

Biopharma manufacturing turbulence boosts inquiries for India-based providers

News

26th Mar, 2024

Biologics will be a major contributor to our growth, says Syngene CEO Jonathan Hunt

News

21st Mar, 2024

Insights

View all

pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs

Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.

28 November 2023

Leveraging High Throughput Screening services to accelerate drug discovery and development

The many applications of HTS and how it has evolved beyond lead identification and candidate optimization today.

18 August 2023

Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer

How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.

19 June 2023

Upcoming events

View all

Festival of Biologics USA

15th to 17th April

San Diego

CPHI Japan

17th to 19th April

Tokyo

Swiss Biotech Day

22nd and 23rd April

Basel

Immuno Oncology Summit Europe 2024

23rd to 25th April

London

World Orphan Drug Congress USA

23rd to 25th April

Boston

Asia Bio Partnering Forum

24th and 25th April

Singapore

Corporate Social Responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.

Governance

Behind consistent growth is good governance

Careers

Discover a world of opportunities

Annual Reports

Touching a billon lives through innnovation

Discovery

Development

Manufacturing

Discovery

Development & Manufacturing

SynVent Integrated Drug Discovery

Emerging Biopharma

Dedicated Centers

Center for Advanced Protein Studies (CAPS)

Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

Full-stack In vitro and Genetic Tox services

Establishing the simple complex

Research that changes the world for the better

Who we are

What we do

Discovery

Development

Manufacturing

Dedicated Centers

InstaVisit – Visit Syngene virtually

Latest News

Indian CDMOs expand capacities with Syngene taking the lead

Biopharma manufacturing turbulence boosts inquiries for India-based providers

Biologics will be a major contributor to our growth, says Syngene CEO Jonathan Hunt

Insights

pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs

Leveraging High Throughput Screening services to accelerate drug discovery and development

Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer

Upcoming events

Corporate Social Responsibility

Syngene International Ltd

Governance

Careers

Annual Reports

Sign-up for our newsletter

Quick links

Business

Get in touch

Other links

To download, Please share your details

This Website uses Cookies

To view or email, Please share your details view

To download, Please share your details